Hidradenitis Suppurativa

This analysis was conducted to evaluate whether genetic risk of hidradenitis suppurativa was linked to greater risk of future cardiometabolic disease.

Contrary to previous research, findings suggest no significant difference in infertility between patients with HS, other dermatological diseases, and healthy controls.

These new data demonstrate that bimekizumab was both effective and well-tolerated over the course of 2 years for patients with hidradenitis suppurativa.

Adding semaglutide to standard hidradenitis suppurative therapies achieved improvements in quality of life and fewer disease-related flares.

A new case-control study reported a higher prevalence of precocious puberty in children and adolescents with HS compared with controls.

These findings resulted from a systematic literature review highlighting the impact of stigma and lack of support on self-image for patients with eczema, psoriasis, HS, and other conditions.

A study involving 6.2 million patients found smoking increases the risk of developing hidradenitis suppurativa, with quitting smoking significantly reducing this risk.

A phase 2 trial shows tofacitinib improves autoimmune conditions in Down syndrome, with notable skin health benefits and a good safety profile.

These data show that izokibep treatment of HS met each of its key primary and key secondary endpoints.

In this analysis, investigators highlighted the perceptions of individuals with HS and atopic dermatitis and assessed higher rates of stigmatization.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

Patients with hidradenitis suppurativa had the greatest risk of developing various CVS, with heart failure being the most common one.

The FDA announcement on bimekizumab’s supplemental Biologics License Application followed the phase 3 BE HEARD I and II studies’ conclusion.

On March 11, 2024, Acelyrin Inc. announced new positive data from clinical trial programs examining their IL-17A inhibitor izokibep in patients psoriatic arthritis and hidradenitis suppurativa.

These findings from AAD 2024 did not include statistically significant infliximab response predictors, though it had been the largest reported cohort on the subject to date.

In this new analysis presented at AAD 2024, patients with HS saw substantial improvements in their hidradenitis suppurativa-related pain following treatment with bimekizumab.

New data presented at AAD 2024 highlights challenges in financial status, insurance and comorbidities among black pediatric patients with HS.

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.

The factors highlighted in this analysis may help dermatologists to better understand the concerns, misconceptions, and perceived risks reported by patients with HS.

The THESEUS study was conducted to look at current HS management and the influences on treatment decisions, with the goal of informing future randomized controlled trials.

In this analysis, the investigators note that the clinical association may be helpful to be taken into account as clinicians treat patients with HS.

These phase 2 data on hidradenitis suppurativa patients highlight new information on the use of lutikizumab as a treatment alternative.

Twice-daily PDE4-inhibition using 10–40 mg of orismilast showed promise though further studies may be necessary to validate these findings.